Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

JPIAMR-ACTION

Financiado

Cerrado

JPIAMR ANTIMICROBIAL TRANSMISSION INTERVENTIONS

In the past 90 years since their discovery, antibiotics have saved millions of lives from bacterial diseases. However, emerging resistance to antimicrobials now threatens many advances achieved in modern medicine. AMR is a critica... ver más

31/12/2026

VETENSKAPSRADET S...

26M€

Presupuesto del proyecto: 26M€

Líder del proyecto

VETENSKAPSRADET SWEDISH RESEARCH COUNCIL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 31 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-01-26

SC1-HCO-07-2020: ERA-NET to support the Joint Progra...

I+D

Cerrada hace 4 años

0% 31% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

31 Participantes

VETENSKAPSRADET SWEDISH RES...

1.05M€ | Lider

TEXTIL TAPIAS

387.21K€ | Participante

THE HEALTH RESEARCH BOARD

181.91K€ | Participante

FRRB

389.81K€ | Participante

Proyectos interesantes

RTC-2017-6601-2

Medical Technol...

Environmental S...

166K€ Cerrado

DESIGN OH AMR

Medical Technol...

Environmental S...

990K€ Cerrado

PID2019-109333RB-I00

Medical Technol...

Data Science

73K€ Cerrado

PID2021-125136OB-I00

Medical Technol...

Environmental S...

145K€ Cerrado

CTM2016-75653-R

Medical Technol...

Environmental S...

155K€ Cerrado

PID2020-118813GB-I00

Medical Technol...

Environmental S...

270K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 71 meses Fecha Inicio: 2021-01-26
Fecha Fin: 2026-12-31

Líder del proyecto

VETENSKAPSRADET SWEDISH RESEARCH COUNCIL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 26M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto In the past 90 years since their discovery, antibiotics have saved millions of lives from bacterial diseases. However, emerging resistance to antimicrobials now threatens many advances achieved in modern medicine. AMR is a critical global health issue tightly linked with the One Health concept, which recognises that human and animal health are inextricably linked, and that diseases are transmitted from humans to animals and vice versa. One Health also encompasses the environment as another link between humans and animals and a potential source and reservoir of AMR. Antimicrobial resistance is a growing global health concern and threatens the future treatment and health of humans and animals. In addition, AMR limits our ability to achieve several of the UN Sustainable Development Goals (SDGs). The global challenge to address AMR goes beyond the production of new antibiotics and therapies. Reducing demand for new antibiotics through public awareness, infection prevention and control, prudent and rational use of antibiotics for humans and animals, as well as effective diagnosis and surveillance of antibiotic-resistant infections and monitoring antibiotic use, are crucial when dealing with this problem globally. The transmission and spread of AMR in and between One Health compartments is complex, which emphasises the need for comprehensive interventions to reverse the trend of increasing human and animal infections resistant to treatment. The ERA-NET Cofund JPIAMR-ACTION will tackle this central challenge by supporting research and innovation for the development and testing of strategies and methodologies to reduce the transmission and spread of AMR within a full One Health spectrum. The JPIAMR-ACTION co-funded call and other activities will be instrumental in producing new innovative approaches, and advancing existing actions towards the development of new and improved interventions to inhibit or limit the development of AMR in humans, animals and the environment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores